BNL Price Prediction Next Week
Analysis and Insights
To predict the stock price of Broadstone Net Lease (BNL) for the next trading week, we analyze both technical indicators and recent news sentiment.
Technical Analysis:
BNL's stock price is currently trading at $16.86, with a 52-week range of $14.205 to $19.15. Key technical indicators include:
- RSI (14): 65.12, indicating neutral momentum.
- MACD: 0.28, showing slight bullish momentum.
- Bollinger Bands: The stock is currently near the lower end of the 20-day Bollinger Band range, suggesting potential support.
Fibonacci Levels:
- Fibonacci R1: 16.9700
- Fibonacci S1: 16.0900
- Fibonacci R2: 17.2400
- Fibonacci S2: 15.8100
The stock is currently testing the Fibonacci S1 level, which could act as a support zone.
News Sentiment:
Recent news highlights BNL's stable cash flow, high-quality tenants, and attractive dividend yield of 7.3%. Analysts have maintained a Hold rating with a price target of $17.00, while the overall consensus suggests a Moderate Buy with an average target of $19.00.
Price Prediction:
Based on the technical indicators and news sentiment, BNL is expected to trade near the Fibonacci S1 level with a slight bullish bias. The predicted price for the next trading week is $17.20.
Recommendation:
Buy BNL at the current price of $16.86, targeting $17.20, as the stock is near support levels with a stable dividend yield and moderate buy consensus.
BNL Similar Chart Price Prediction
The price of BNL is predicted to go up 6.09%, based on the high correlation periods with ACCO. The similarity of these two price pattern on the periods is 97.94%.
BNL
ACCO
Up: 6.09%Similarity: 97.94%
BNL Revenue Forecast
BNL EPS Forecast
BNL FAQs
What is BNL revenue forecast for next quarter？
BNL Analyst's Forecast
Mitch Germain
JMP Securities
Hold → Buy
2024-12-17
Price Target
$21
Upside
+25.04%
JMP Securities analyst Mitch Germain upgraded Broadstone Net Lease to Outperform from Market Perform with a $21 price target. The firm believes progress from the company's portfolio rationalization strategy is not priced into the shares. JMP has "been impressed" by Broadstone 's progress in reducing exposure to clinical healthcare assets, and says the company's investment pipeline is expanding and should result in improved quality of rents.
Michael Goldsmith
UBS
Hold
2024-11-14
Price Target
$18
Upside
+6.16%
